The China biologics contract manufacturing market, valued at USD 5.7 billion in 2025, is projected to reach USD 6.5 billion in 2026 and USD 15.5 billion by 2035, with a 10.2% CAGR during the forecast period 2026 to 2035. It is worth noting that till date, over 25 biologics and biosimilar products have been approved in China. In addition, close to 1,000 clinical trials, investigating a variety of biologics and biosimilars for treating a diverse range of diseases, are presently underway in this re...

New coronavirus (COVID-19) is a previously unidentified strain of coronavirus, that first emerged in the Chinese city of Wuhan in December 2019. On 30th January 2020, the WHO declared the coronavirus outbreak as a global health emergency. In fact, the virus is estimated to have infected more than 45,000 individuals, around the globe (estimates till the second week of February 2020). Consequently, more than 35 pharmaceutical / biotechnology companies, government agencies, and research institutes...

The China pharmaceutical contract manufacturing market is estimated to be worth $5.5 billion in 2020 and is expected to grow at CAGR of 9% during the forecast period. Over the past few decades, the pharmaceutical market in China has evolved into the second largest in the world; as per certain industry experts, it is estimated to surpass USD 300 billion by the end of 2020. Moreover, the number of FDA approved API CMO manufacturing facilities in the region has doubled during the period 2010-2019....

The cell reprogramming market is estimated to be worth $1.16 billion in 2020 and is expected to grow at compounded annual growth rate (CAGR) of 8% during the forecast period. Stem cell-based treatments are known for their ability to replace damaged cells and tissues, thereby, effectively reversing the adverse physiological effects they cause. The discovery of induced pluripotent stem cells (iPSCs) by Shinya Yamanaka

The fragment based drug discovery market is estimated to be worth $596 million in 2020 and is expected to grow at CAGR of 11% during the forecast period. Drug discovery and development is a complex and tedious process that requires a significant amount of resources and capital investment (~USD 2.6 billion). Specifically, in 2019, R&D spending was estimated to be around USD 182 billion, with more than 16,000 drug molecules evaluated during the course of the whole year. As a result, the industry...

The global prefilled syringe fill finish manufacturing market, valued at USD 1.8 billion in 2025, is projected to reach USD 2.0 billion in 2026 and USD 2.9 billion by 2030, with a 9.4% CAGR during the forecast period 2026 to 2030. Prefilled syringe fill finish manufacturing is considered to be one of the most crucial steps in the pharmaceutical production process. Proper prefilled syringe fill finish, carried out under aseptic conditions, is a necessity for not only maintaining pharmacological e...

The peptide drug discovery market is estimated to be worth $560 million in 2020 and is expected to grow at compounded annual growth rate (CAGR) of 10.5% during the forecast period. Over the past few years, peptides and macrocycle-based pharmacological interventions have gained a lot of attention from clinical researchers. In fact, more than 60 peptide-based therapies and macrocycle drug molecules have been approved till date, across the globe. In addition, more than 400 peptide based drugs are...

The computer aided drug discovery market is estimated to be worth $29 million in 2020 and is expected to grow at CAGR of 15.6% till 2030. The process of drug development, beginning from the discovery of a pharmacological lead to its commercial launch, is estimated to take around 10-15 years, involving capital investments in the range of USD 4-10 billion. Over time, the complexities of drug discovery, have increased; this is especially true for large molecules, which are inherently more complex t...

The ophthalmic drugs contract manufacturing market is estimated to be worth $0.79 billion in 2020 and is expected to grow at CAGR of 8% during the forecast period. According to the World Health Organization

The regulatory affairs management for medical devices market, valued at USD 594 billion in 2025, is projected to reach USD 633 billion in 2026 and USD 819 billion by 2030, with a 6.7% CAGR during the forecast period 2026 to 2030. According to the World Bank, more than 50,000 different types of medical devices are currently being used on a daily basis in healthcare facilities across the globe. Moreover, in 2018, the USFDA approved over 130 medical devices. However, a relatively large proportion...

The vaccine delivery devices market is estimated to be worth $1.5 billion by 2030, driven by the increase in global vaccination coverage. Data presented by the WHO indicates that the current global vaccination coverage is nearly 85%. Moreover, recent global immunization records indicate that more than 115 million children were immunized against diphtheria, tetanus and pertussis in 2018. As a result, significant efforts have been put into the development of drug delivery technologies / devices, s...

The global PARP inhibitors market is estimated to grow from USD 7.5 billion in 2024 to reach USD 8.5 billion in 2025 and USD 23.6 billion by 2035, representing a higher CAGR of 10.8% during the forecast period. Currently, there are four approved (and marketed) poly-ADP ribose polymerase (PARP) inhibitor drugs, which have been shown to operate based on the concept of synthetic lethality. Further, several such PARP inhibitors drugs are being investigated for the treatment of a myriad of advanced o...

Natural killer (NK) cells, or killer (K) cells, represent an important subset of cellular mediators of the innate immune system. Technically, they are classified as group I innate lymphocytes. Additionally, studies have demonstrated that NK cells can also secrete certain cytokines and chemokines, such as IFN? and TNF?, through which they can recruit other immune components to augment and sustain an immune response. Currently, these cells are being evaluated across multiple clinical trials to tr...

The global neoantigen targeted therapies market, valued at USD 661 million in 2025, is projected to reach USD 807 million in 2026 and USD 2,913 billion by 2030, with a 38% CAGR during the forecast period 2026 to 2030. Cancer is known to be one of the leading causes of death worldwide, accounting for 0.6 million deaths in 2018, in the US alone. The WHO has estimated the number of new cancer cases, reported across the globe, to rise by 70% over the next 20 years. Notably, amongst the targeted ant...

The clinical trial services market is estimated to be worth $9 billion in 2050 and is expected to grow at CAGR of over 14.1% during the forecast period. Estimates suggest that nearly 85% of clinical trials fail to retain enough patients for successful study conduct. Patient recruitment and retention-related concerns have been associated with massive delays, with over 90% of clinical trials failing to comply to predetermined completion dates. Such delays are estimated to result in capital losses...

Depression is a chronic medical condition characterized by a persistent feeling of sadness and lack of interest in external stimuli. It has been estimated that over 300 million people (considering all age groups) suffer from depression worldwide. Further, depression and other depressive disorders are projected to be responsible for an economic burden of up to USD 210 billion per year in the US. Despite the high prevalence and significant impact of this disease, less than 50% of affected individu...

The companion diagnostics market revenue is estimated to be reach $6 billion by 2030, driven by the companion diagnostics for oncology market segment. Over the years, many cases have been identified where conventional treatment options have failed to demonstrate any therapeutic benefit. It is estimated that nearly 50% of prescribed drugs / therapies fail to show adequate clinical benefits. Further, a study of nearly 200 unique pharmacological interventions, across 670 clinical trials, concluded...

The global stem cell therapy market for cardiovascular and metabolic disorders is likely to grow to $3.3 billion by 2030, driven by the rising incidence of these disorders. Cardiovascular disorders and metabolic disorders are considered to be amongst the leading causes of death worldwide. According to a study conducted by RTI International for the American Heart Association, the prevalence of cardiovascular diseases is expected to rise to 45% of the overall US population, while affiliated costs...

The blockchain in genomic data management market, valued at USD 294.5 million in 2024, is projected to grow to USD 524.2 million in 2025 and USD 19,831.6 million by 2035, representing a CAGR of 43.8% during the forecast period. Blockchain technology has emerged as a viable option to store / exchange genomic data. The decentralized information management model used in blockchains has demonstrated significant benefits in banking and the fintech industry. Moreover, cryptocurrencies, which are based...

The extractable and leachable testing market is estimated to be worth $1 billion in 2028, growing at CAGR of 9.9 % during the forecast period. Notably, in 2010, McNeil Consumer Healthcare was compelled to recall more than 500 lots of Tylenol, Motrin, Benadryl and Zyrtec upon being made aware of the presence of an antifungal chemical, called 2, 4, 6-tribromoanisole (which is used to chemically treat shipping pallets), in the aforementioned product formulations. It is worth highlighting that this...